The biotech stock's price-to-earnings-to-growth (PEG) ratio is a super-low 0.58, according to the London Stock Exchange Group (LSEG). Any PEG ratio below 1.0 is viewed as an attractive valuation.

The FDA should have more big news for Vertex only a few weeks later. It expects to announce an approval decision on ...

Ginkgo Bioworks is pivoting: Once a synthetic biology darling, the flailing company has now turned to AI-driven protein ...

The good news is that if you're willing to put in a bit of effort, it's very possible to improve on your process to secure ...

Collaboration between giant pharmaceutical corporations and patients with very little power just doesn’t work, according to ...

Industry insiders hope the Fed’s decision to cut rates for the first time in years will boost biotech investment. But the long-awaited move won’t cure all that ails the sector, others cautioned.

BioPhy was founded by a Wharton grad and former Johnson & Johnson engineer, the latest guest on the Founding Philly podcast.

The drop in interest rate is slightly bigger than anticipated and good news for the biotech industry, but little will change ...

EQS-News: BRAIN Biotech AG / Key word (s): Contract BRAIN Biotech AG concludes major pharma compound transaction valued up to EUR 128.88 million from its BioIncubator 20.09.2024 / 19:50 CET/CEST ...

In the world of pharmaceuticals, companies aim to operate under GMP guidelines — a set of production and manufacturing ...

Many HCPs now place greater importance on pharmaceutical companies that integrate patients within the continuum of care.

With a market capitalization of just $1.9 billion, Recursion still provides a potentially good entry point for investors, but that's only if there are good reasons to think that its strategy will pan ...